LTR Pharma (ASX:LTP) has increased its ownership in sustainable biotechnology company LevOmega from 33 to approximately 43 per cent, following a $1 million strategic investment through its subsidiary LTR Spectrum.
The investment strengthens LevOmega’s development of pharmaceutical-grade, nature-identical omega-3 ingredients and reinforces LTR Pharma’s strategy of building a portfolio of first-in-class solutions addressing significant, global unmet needs. It follows LevOmega’s successful capital raise, which will fund research, technical validation, pilot production and commercialisation.
LevOmega was co-founded by LTR Pharma, Levur and Green Blue Health, with a focus on developing scalable, sustainable omega-3 products that replicate the composition and function of marine-derived oils without relying on ocean harvesting.
Global demand for omega-3 oils continues to grow, driven by their cardiovascular and anti-inflammatory benefits, but traditional fish-oil supply chains are under increasing pressure from overfishing, pollution and declining ocean yields. Studies show that global nutritional requirements for essential fatty acids such as EPA and DHA already exceed sustainable marine supply, underscoring the need for alternatives.
LTR Pharma Executive Chairman Lee Rodne said the investment represented both a strategic and ethical alignment with the company’s mission. “We are delighted to deepen our commitment to LevOmega. This investment not only increases our equity stake to around 43 per cent but also provides LevOmega with the resources to accelerate development of pharmaceutical-grade omega-3 products at a time when traditional fish oil supply chains are under increasing pressure,” Mr Rodne said. “For LTR Pharma, this investment underscores our ability to identify and support scalable, first-in-class solutions that address global sustainability challenges while remaining highly complementary to our core intranasal pharmaceutical pipeline.”
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, while OROFLOW is in development for oesophageal motility disorders.